chronic pain chronic pain
Conditions
Interventions
None listed
Sponsors
Mikawa Yasuhito
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patients for whom standard drug treatments have not been effective 2) Patients for whom there is currently no appropriate treatment 3) Patients who refuse to use standard treatments due to allergies or other reasons
Exclusion criteria
Exclusion criteria: 2) Patients currently participating in another clinical trial, or patients who have previously participated in a clinical trial and for whom more than one month has not yet passed since the last dose of the study drug. 3) Patients who are pregnant, likely to be pregnant, or breastfeeding. 4) Patients with severe liver or kidney disorders. 5) Patients who are unable to participate in the study or whose legal representative is unable to participate in the study via online medical consultation, online electronic registration, data entry, or internet transmission. 6) Patients who are deemed inappropriate by the principal investigator or co-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The progression of chronic pain will be assessed using the Numerical Rating Scale (NRS), an international pain assessment scale, and inflammatory markers (CRP) will be measured through blood tests to comprehensively evaluate safety and efficacy. | — |
Secondary
| Measure | Time frame |
|---|---|
| As a secondary evaluation indicator, adverse event indicators such as CTCAE (Common Terminology Criteria for Adverse Events) will be used. | — |
Contacts
Public ContactHideo Kobayashi
JSCSF Japan Society of Clinical Study for Frontier-Medicine
Outcome results
None listed